<DOC>
	<DOCNO>NCT02287194</DOCNO>
	<brief_summary>To document indication cholangioscopy clinical utility SpyGlass Direct Visualization System China use per standard practice . Prospective , Post market , Multi-center , Non-randomized Study</brief_summary>
	<brief_title>SpyGlass Direct Visualization System Clinical Registry China</brief_title>
	<detailed_description>Patients present indication cholangioscopy present possible indication cholangioscopy determine ERCP procedure immediately precede SpyGlass procedure join study , totally 500 patient across 16 site throughout China participate study . After SpyGlass operation , patient follow 72 hour observe adverse event , patient indeterminate stricture undefined fill defect indication tissue sample yield histopathology positive malignancy unresolved device and/or procedure relate SAE 72 Hours continue follow 6 month . Finally , procedure success rate analyze primary endpoint , SAEs impact patient management analyze secondary endpoint .</detailed_description>
	<mesh_term>Biliary Tract Diseases</mesh_term>
	<criteria>1 . Age 18 85 . 2 . Willing able provide write informed consent participate study . 3 . Willing able comply study procedure . 4 . Indicated ERCP cholangioscopy indicate ERCP suspect need cholangioscopy . 1 . Endoscopic technique contraindicate . 2 . ERCP contraindicate 3 . A medical condition warrant use device outside indication use . 4 . Requirement anticoagulation safely stop least 7 day prior procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>